If Koos gets a reasonable offer, he will sell. RGBP is cash poor and doesn't have the research or clinical team currently to push forward with clinical trials. Selling is their best option. They just can't give it away, though. I think a buyout has to be for at least $7 billion. And that's absolute minimum.
Market Data 
Markets 
AI
